Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its portfoilio.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
A recent trial showed its new 2-for-1 injection was more effective on both illnesses than existing individual shots.
The regulator sees some patents as ploys to keep companies from developing cheaper generic versions of 20 different brand-name drugs.